BioArctic

BioArctic EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 18.44. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -116.61 — a change of -115.81% (higher).

EV/EBITDA

18.44

YoY

-115.81%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of BioArctic is 2025 18.44 . EV/EBITDA (Enterprise Value to EBITDA) of BioArctic was 2024 -116.61 . It decreases by -115.81% higher compared to the previous year.

The BioArctic EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
53.80 SEK
Jan 1, 2019
214.28 SEK
Jan 1, 2020
-353.89 SEK
Jan 1, 2021
-209.93 SEK
Jan 1, 2022
5,940.35 SEK
Jan 1, 2023
96.90 SEK
Jan 1, 2024
-116.61 SEK
Jan 1, 2025
18.44 SEK
The BioArctic EV/EBITDA history
YEAREV/EBITDAYoY
18.44-115.81%
-116.61-220.35%
96.90-98.37%
5,940.35-2,929.64%
-209.93-40.68%
-353.89-265.15%
214.28+298.32%
53.80-95.44%
1,179.24+236.74%
350.19-91.80%
4,272.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EV/EBITDA (Enterprise Value to EBITDA) of BioArctic is 18.44 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of BioArctic changed from -116.61 to 18.44, representing a -115.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) BioArctic since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioArctic

All Key Metrics — BioArctic